|Home | Contact | Site Map|
Advantek's Patent on Method for Making Alpha-1-Protease Inhibitor Granted by the Chinese State Intellectual Property Office
Hong Kong (06 March 2007) - Hong Kong (06 Mar 2007) - Advantek Biologics Limited announced today that the company's patent application (No. 200410031057.4) entitled "Method for the manufacture of a therapeutic protease inhibitor" was granted approval by the State Intellectual Property Office of P. R. China. The patent application was originally filed on 12 Apr 2004. Another concurrent patent application (No. 200610082946.2) on the quantification of alpha-1-protease inhibitor remains approval-pending.About Alpha-1-Protease Inhibitor
Alpha-1-protease inhibitor is an abundant plasma protein protecting tissues from being broken down by the body's natural enzymes, such as neutrophil elastase. An inherited disorder (Alpha-1-Protease Inhibitor Deficiency) can lead to damage in the lungs (emphysema) as well as the liver, and administration of this protein may prevent such damage.About Advantek
Advantek Biologics Limited is engaged in the R&D, commercialization, manufacture, marketing and sale of plasma-derived therapeutics, and biochemicals. Advantek is the first and only Hong Kong-based biopharmaceutical manufacturer. To reflect a mission of bringing safe biopharmaceuticals to patients in need, particularly those living in developing countries, Advantek has adopted "Saving Lives Through Safe Biologics" as corporate motto.
Disclaimer: The content of this news release does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred. Statements in this news release that are not strictly historical may be forward-looking statements. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties. The parties undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. The parties believe that contents of this press release are accurate and however, make no representations or warranties about the completeness or the accuracy or any other matter.